Ashvattha Therapeutics to Present at 2021 AACR Virtual Special Conference on Radiation Science and Medicine

Ashvattha Therapeutics to Present at 2021 AACR Virtual Special Conference on Radiation Science and Medicine




Ashvattha Therapeutics to Present at 2021 AACR Virtual Special Conference on Radiation Science and Medicine

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Ashvattha Therapeutics, a biotech company focused on targeting diseased tissues to minimize off target toxicity and expand the therapeutic index for a wide range of drugs using novel hydroxyl dendrimer therapeutics (HDT). Preclinical results on an HDT designed to target and image brain tumors and brain metastases after systemic administration will be presented at the AACR Virtual Special Conference on Radiation Science and Medicine, held March 2-3, 2021.

The first AACR Virtual Special Conference on Radiation Science and Medicine, in association with the AACR Radiation Science and Medicine Working Group, will be an interdisciplinary review of the current and future use of radiation in cancer care. The conference research topics span basic, translational, and clinical radiation advances to foster discussions among radiation scientists at all career stages.

Full details of the virtual presentation are as follows:

Abstract Title: Selective Targeting and Imaging of Orthotopic Glioblastoma after a Single Systemic Dose of a Novel Hydroxyl Dendrimer Radionuclide

Date: March 2, 2021 on-demand
Location:
AACR Virtual Special Conference on Radiation Science and Medicine: https://www.aacr.org/meeting/radiation-science-and-medicine/

“We’re excited to present this data at the first AACR Special Conference on Radiation Science and Medicine, which shows that our novel HD imaging agent D-B483 (HD6-DOTA-111In) selectively targets brain tumors and metastases after a bolus IV injection. Noninvasive imaging techniques are important in diagnosing and treating brain cancer. We have demonstrated that D-B483 persists in the tumor for more than seven days, yielding a high signal (>8 fold) relative to normal brain tissue. We look forward to submitting an IND later this year, to evaluate D-B483 in patients with brain tumors and metastases,” said Jeffrey Cleland, Ph.D., Chairman, Chairman, CEO & President at Ashvattha Therapeutics, “We will then be able to treat these patients with HDTs designed to treat the brain cancer.”

About Ashvattha Therapeutics

Ashvattha Therapeutics, a clinical-stage biopharmaceutical company, is developing novel therapeutics that target and alter specific cells in areas of diseased tissues. The Company’s targeted platform technology, hydroxyl dendrimers (HD), is exclusively licensed from Johns Hopkins University. HDs chemically conjugated to disease modifying drugs create novel proprietary HD therapeutics (HDTs). Ashvattha has initiated multiple programs with HDTs focused on oncology, age-related macular degeneration (AMD), hyperinflammation in diseases such as COVID-19 and neuroinflammatory diseases such as ALS and Alzheimer’s disease. For more information, visit: www.avttx.com.

Contacts

Investors

Matt Brewer

Ashvattha Therapeutics

matt@avttx.com
303-717-9446

Media

Kimberly Ha

KKH Advisors

kimberly.ha@kkhadvisors.com
917-291-5744